drugset
Drugs / HB02
last change Dec 2021 re-read 3 minutes ago

HB02

Vaccine

Developed for
COVID-19
Investigated by
Abu Dhabi Health Services Company · Beijing Institute of Biological Products Co Ltd. · China National Biotec Group Company Limited · G42 Healthcare Research Technology Projects LLC · Wuhan Institute of Biological Products Co., Ltd

Trials 1

today NCT04510207 · Ph 3
202120222023202420252026
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 3 NCT04510207 Jul 2020 → Jun 2021 COVID-19 China National Biotec Group Company Limited Completed Met primary

Press releases naming this drug 1 release

DateIssuerRelease
2018-09-10 HbO2 Therapeutics LLC Hb02 Therapeutics’ Products Become Element #47 In The Periodic Table Of Disruptive Technologies hbo2therapeutics.com ↗

Evidence & citations 3 cited values

Every value below carries the sentence it was read from. 2 sources stand behind the page.

FieldValueCited text
Known as HB02 “Participants were randomized to receive 1 of 2 inactivated vaccines developed from SARS-CoV-2 WIV04 (5 µg/dose; n = 13 459) and HB02 (4 µg/dose; n = 13 465) strains or an...” PMID 34037666 ↗ Jul 2021
Modality Vaccine “inactivated SARS-CoV-2 vaccines” NCT04510207 ↗
Route Intramuscular “they received 2 intramuscular injections 21 days apart” PMID 34037666 ↗ Jul 2021